A correlate of protection for SARS-CoV-2 vaccines is urgently needed
- 8 July 2021
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 27 (7), 1147-1148
- https://doi.org/10.1038/s41591-021-01432-4
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Evidence for antibody as a protective correlate for COVID-19 vaccinesVaccine, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patientsPublished by Cold Spring Harbor Laboratory ,2021
- Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant RecipientsJAMA, 2021
- Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patientsPublished by Cold Spring Harbor Laboratory ,2021
- Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2Published by Cold Spring Harbor Laboratory ,2021
- WHO International Standard for anti-SARS-CoV-2 immunoglobulinThe Lancet, 2021
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020
- Nomenclature for Immune Correlates of Protection After VaccinationClinical Infectious Diseases, 2012
- Correlates of Protection Induced by VaccinationClinical and Vaccine Immunology, 2010